IMMURON LIMITED revenue for the last year amounted to 4.90 M AUD, the most of which — 4.90 M AUD — came from its highest performing source at the moment, Hyper-immune Products, the year earlier bringing 1.80 M AUD. The greatest contribution to the revenue figure was made by Australia — last year it brought IMMURON LIMITED 3.75 M AUD, and the year before that — 1.16 M AUD.